RxDoctor Payments DataLook up a doctor →

Lori Foster, NP

Registered Nurse · Roanoke, VANPI 1871584102

Payments from drug & device makers

$9,820in general payments, 2019–2025

Across 565 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Dexcom, Inc.$953
  • Lilly USA, LLC$814
  • AstraZeneca$725
  • AbbVie$637
  • Abbott$519
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$9,68999%
  • Education$120%
  • Gifts$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,820 in reported general payments places this provider in the 95th percentile of 58 registered nurse providers in Virginia.

See all registered nurse providers in Virginia

Medicare billing

Part B allowed, 2024
$59,695
Medicare patients
333
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$71,432
MounjaroTirzepatide56$57,334
JardianceEmpagliflozin23$34,832
EliquisApixaban20$24,766
Novolog FlexpenInsulin Aspart13$2,582
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,322
Estradiol26$1,504
Venlafaxine Hcl ErVenlafaxine Hcl14$1,465
PaxlovidNirmatrelvir/Ritonavir13$1,429
Escitalopram Oxalate57$1,068
Levothyroxine Sodium76$979
Atorvastatin Calcium90$864
Montelukast Sodium63$840
Bupropion XlBupropion Hcl31$779
Losartan Potassium89$767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,065$71,43245 claims
Lilly USA, LLCMounjaro$814$57,33456 claims
Boehringer IngelheimJardiance$196$34,83223 claims
PfizerEliquis, Paxlovid$437$26,19533 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$108$97976 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 registered nurse providers in Virginia.

Other registered nurse in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →